Generex to Participate in Canadian Diabetes Association Conference

WORCESTER, Mass., Oct. 20 /PRNewswire/ — Generex Biotechnology
Corporation (Nasdaq: GNBT, www.generex.com) today announced
that it will be attending the 13th Annual Canadian Diabetes
Association (CDA) (www.diabetes.ca) / Canadian
Society of Endocrinology and Metabolism (CSEM) (www.endo-metab.ca)
Professional Conference and Annual Meetings in Edmonton, Alberta.
 The gathering will run from October 20-23, 2010 at the Shaw
Conference Centre (9797 Jasper Avenue Northwest, Edmonton).

At booth 437/536, Generex will provide the internationally
renowned community of educators, clinicians, and scientists in
attendance the chance to learn about the Company’s advancements in
the field of diabetes.  Information and one-on-one Q&A
opportunities will be available on Generex Oral-lyn™, the
Company’s buccal insulin spray, as well as our proprietary consumer
product, Glucose RapidSpray™ (www.glucoserapidspray.com).

“This conference is an excellent forum for exchanging ideas and
experiences with our peers about how to advance diabetes treatments
to the next level,” said Mark Fletcher, the Generex Interim
President & Chief Executive Officer.  “We are particularly
looking forward to show-casing Generex Oral-lyn™, which is in
the late stages of a global, pivotal Phase III clinical trial.”
 

Highlights of the conference will include speaker forums
addressing current diagnosis and treatment issues, interactive
workshops, oral abstract sessions, poster presentations, a trade
show, and sponsored social activities.

About Generex Biotechnology Corporation

Generex is engaged in the research, development, and
commercialization of drug delivery systems and technologies.
 Generex has developed a proprietary platform technology for
the de

‘/>”/>

SOURCE